Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).

Ran Jin,Adesuwa S Ogbomo,Neil A Accortt,Lincy S Lal,Geetanjali Bishi,Darcie Sandschafer,Jerome H Goldschmidt

Therapeutic advances in medical oncology（2023）

引用 1|浏览1

暂无评分

摘要

In this real-world cohort of mCRC patients who were treated 1L with a bevacizumab biosimilar (bevacizumab-awwb), the clinical effectiveness and tolerability data were as expected and consistent with previously published findings from real-world studies of bevacizumab RP in mCRC patients.

查看译文

关键词

metastatic colorectal cancer,colorectal cancer,bevacizumab biosimilar,real-world,bevacizumab-awwb

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要